Literature DB >> 21756950

Receptor-mediated activation of a proinsulin-transferrin fusion protein in hepatoma cells.

Yan Wang1, Yu-Sheng Chen, Jennica L Zaro, Wei-Chiang Shen.   

Abstract

A proinsulin-transferrin (ProINS-Tf) recombinant fusion protein was designed and characterized for the sustained release of an active form of insulin (INS) by hepatoma cells. During incubation with H4IIE hepatoma cells, a gradual decline of ProINS-Tf concentration, with a concomitant generation of the immuno-reactive insulin-transferrin (irINS-Tf), was detected in the culture medium by using INS- or proinsulin (ProINS)-specific radioimmunoassay (RIA) system. Further studies indicated that the conversion of ProINS-Tf to irINS-Tf was a transferrin receptor (TfR) mediated process that was pH-sensitive, and temperature- and microtubule-dependent. These results suggest that the conversion occurred during the slow recycling route of transferrin (Tf)-TfR pathway, possibly processed by proteases in the slow recycling compartments juxtaposed to the trans-Golgi network (TGN). ProINS-Tf exhibited little activity in the short-term promotion of glucose uptake in adipocytes, indicating that it was in an inactive form similar to ProINS. Stimulation of Akt phosphorylation by ProINS-Tf was detected only after prolonged incubation with H4IIE cells. On the other hand, ProINS-Tf pre-incubated with H4IIE cells for 24h acquired an immediate activity of stimulating Akt phosphorylation. Furthermore, ProINS-Tf elicited a strong activity in the inhibition of glucose production following 24h incubation with H4IIE cells. Based on these findings, we conclude that the Tf-TfR endocytosis and recycling pathway enables the conversion and release of ProINS-Tf in an active form of irINS-Tf. Results from this study suggest that the Tf-TfR pathway can be exploited for the design of prohormone-Tf fusion proteins as protein prodrugs for their sustained and targeted activation.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21756950      PMCID: PMC3196267          DOI: 10.1016/j.jconrel.2011.06.029

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  33 in total

1.  Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum.

Authors:  V M Rivera; X Wang; S Wardwell; N L Courage; A Volchuk; T Keenan; D A Holt; M Gilman; L Orci; F Cerasoli; J E Rothman; T Clackson
Journal:  Science       Date:  2000-02-04       Impact factor: 47.728

2.  TNF-α induced apoptosis is accompanied with rapid CD30 and slower CD45 shedding from K-562 cells.

Authors:  Vladimir Jurisic; Tatjana Srdic-Rajic; Gordana Konjevic; Gordana Bogdanovic; Mija Colic
Journal:  J Membr Biol       Date:  2011-01-11       Impact factor: 1.843

3.  Activation of CD95L fusion protein prodrugs by tumor-associated proteases.

Authors:  I Watermann; J Gerspach; M Lehne; J Seufert; B Schneider; K Pfizenmaier; H Wajant
Journal:  Cell Death Differ       Date:  2006-10-20       Impact factor: 15.828

4.  Insulin delivery with plasmid DNA.

Authors:  A M Abai; P M Hobart; K M Barnhart
Journal:  Hum Gene Ther       Date:  1999-11-01       Impact factor: 5.695

5.  Effects of receptor binding on plasma half-life of bifunctional transferrin fusion proteins.

Authors:  Xiaoying Chen; Hsin-Fang Lee; Jennica L Zaro; Wei-Chiang Shen
Journal:  Mol Pharm       Date:  2011-02-22       Impact factor: 4.939

Review 6.  Recombinant human transferrin: beyond iron binding and transport.

Authors:  Martin E Brandsma; Anthony M Jevnikar; Shengwu Ma
Journal:  Biotechnol Adv       Date:  2010-12-13       Impact factor: 14.227

7.  ATTEMPTS: a heparin/protamine-based prodrug approach for delivery of thrombolytic drugs.

Authors:  J F Liang; Y J Park; H Song; Y T Li; V C Yang
Journal:  J Control Release       Date:  2001-05-14       Impact factor: 9.776

8.  Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides.

Authors:  Byung-Joon Kim; Jie Zhou; Bronwen Martin; Olga D Carlson; Stuart Maudsley; Nigel H Greig; Mark P Mattson; Ellen E Ladenheim; Jay Wustner; Andrew Turner; Homayoun Sadeghi; Josephine M Egan
Journal:  J Pharmacol Exp Ther       Date:  2010-05-24       Impact factor: 4.030

9.  Angiopoietin-related growth factor suppresses gluconeogenesis through the Akt/forkhead box class O1-dependent pathway in hepatocytes.

Authors:  Masashi Kitazawa; Yasushi Ohizumi; Yuichi Oike; Takanori Hishinuma; Seiichi Hashimoto
Journal:  J Pharmacol Exp Ther       Date:  2007-09-05       Impact factor: 4.030

10.  Processing and release of human proinsulin-cleavage products into culture media by different engineered non-endocrine cells: a specific assessment by capillary electrophoresis.

Authors:  C Arcelloni; L Falqui; S Martinenghi; A Stabilini; A E Pontiroli; R Paroni
Journal:  J Endocrinol       Date:  2000-08       Impact factor: 4.286

View more
  7 in total

Review 1.  Tissue barriers and novel approaches to achieve hepatoselectivity of subcutaneously-injected insulin therapeutics.

Authors:  Juntang Shao; Jennica L Zaro; Wei-Chiang Shen
Journal:  Tissue Barriers       Date:  2016-03-04

Review 2.  Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters.

Authors:  William R Strohl
Journal:  BioDrugs       Date:  2015-08       Impact factor: 5.807

3.  Proinsulin-transferrin fusion protein as a novel long-acting insulin analog for the inhibition of hepatic glucose production.

Authors:  Yan Wang; Juntang Shao; Jennica L Zaro; Wei-Chiang Shen
Journal:  Diabetes       Date:  2013-12-18       Impact factor: 9.461

4.  Enhanced insulin receptor interaction by a bifunctional insulin-transferrin fusion protein: an approach to overcome insulin resistance.

Authors:  Yuqian Liu; Hsuan-Yao Wang; Juntang Shao; Jennica L Zaro; Wei-Chiang Shen
Journal:  Sci Rep       Date:  2020-05-07       Impact factor: 4.379

5.  Seed- and leaf-based expression of FGF21-transferrin fusion proteins for oral delivery and treatment of non-alcoholic steatohepatitis.

Authors:  Hsuan-Wu Hou; Christopher A Bishop; Jana Huckauf; Inge Broer; Susanne Klaus; Henrik Nausch; Johannes F Buyel
Journal:  Front Plant Sci       Date:  2022-09-29       Impact factor: 6.627

6.  Characterization and Oral Delivery of Proinsulin-Transferrin Fusion Protein Expressed Using ExpressTec.

Authors:  Yu-Sheng Chen; Jennica L Zaro; Deshui Zhang; Ning Huang; Andrew Simon; Wei-Chiang Shen
Journal:  Int J Mol Sci       Date:  2018-01-26       Impact factor: 5.923

7.  Discovery of An Orally Effective Factor IX-Transferrin Fusion Protein for Hemophilia B.

Authors:  Chen Xie; Zhijun Wang; Yang Su; Jeffrey Wang; Wei-Chiang Shen
Journal:  Int J Mol Sci       Date:  2019-12-18       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.